-
1.发明专利Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids 有权使用RITONAVIR（ABT-538）改善细胞色素P450在治疗艾滋病方法中代谢药物的药代动力学
公开(公告)号：JP2007291131A
公开(公告)日：2007-11-08
申请号：JP2007173713
申请日：2007-07-02
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor： NORBECK DANIEL W , KEMPF DALE J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/427 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4427 , A61K31/444 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/18 , A61P43/00 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
CPC classification number: A61K31/453 , A61K31/337 , A61K31/341 , A61K31/395 , A61K31/426 , A61K31/44 , A61K31/498 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To provide a method for improving the pharmacokinetics of drugs metabolized by cytochrome P450 monooxygenases. SOLUTION: The method comprises combination administration of ritonavir or a pharmaceutically acceptable salt thereof. When the ritonavir is administered in combination with drugs metabolized by the cytochrome P450 monooxygenases, two sorts of these therapeutic agents can be prescribed as a separate formulation administered at a simultaneous or different time, or these two sorts of therapeutic agents can be administered as a single formulation. COPYRIGHT: (C)2008,JPO&INPIT
Abstract translation: 要解决的问题：提供一种改善由细胞色素P450单加氧酶代谢的药物的药代动力学的方法。 解决方案：该方法包括联合施用利托那韦或其药学上可接受的盐。 当利托那韦与由细胞色素P450单加氧酶代谢的药物组合施用时，可以将两种这些治疗剂作为在同时或不同时间施用的分开的制剂来处方，或者这两种治疗剂可以单独施用 公式。 版权所有（C）2008，JPO＆INPIT
-
2.发明专利Use of ritonavir (abt-538) for improving pharmacokinetic of drug metabolized by cytochrome p450 in method of treating aids 审中-公开使用RITONAVIR（ABT-538）改善细胞色素P450在治疗艾滋病方法中代谢药物的药代动力学
公开(公告)号：JP2012111775A
公开(公告)日：2012-06-14
申请号：JP2012022128
申请日：2012-02-03
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor： NORBECK DANIEL W , KEMPF DALE J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/427 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61K45/00 , A61P31/12 , A61P31/18 , A61P43/00 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
CPC classification number: A61K31/453 , A61K31/337 , A61K31/341 , A61K31/395 , A61K31/426 , A61K31/44 , A61K31/498 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To provide a method for improving pharmacokinetics of drugs which are metabolized by cytochrome P450 monooxygenases.SOLUTION: The method comprises administering a combination of: the drugs which are metabolized by cytochrome P450 monooxygenases or pharmaceutically acceptable salts thereof; and ritonavir or a pharmaceutically acceptable salt thereof.
Abstract translation: 要解决的问题：提供一种改善由细胞色素P450单加氧酶代谢的药物的药代动力学的方法。 解决方案：该方法包括施用以下组合：由细胞色素P450单加氧酶代谢的药物或其药学上可接受的盐; 和利托那韦或其药学上可接受的盐。 版权所有（C）2012，JPO＆INPIT
-
公开(公告)号：DE69637511T2
公开(公告)日：2009-06-04
申请号：DE69637511
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALES J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/426 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/13 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
Abstract: There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.
-
公开(公告)号：DK1284140T3
公开(公告)日：2008-08-18
申请号：DK02079003
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： KEMPF DALES J , LEONARD JOHN M , BERTZ RICHARD J , NORBECK DANIEL W
IPC: A61K31/426 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/13 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
Abstract: There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.
-
公开(公告)号：AT392895T
公开(公告)日：2008-05-15
申请号：AT02079003
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALES J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/426 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/13 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
Abstract: There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.
-
Patent Agency Ranking
公开(公告)号：DK0871465T3
公开(公告)日：2003-02-03
申请号：DK96922604
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALE J , LEONARD JOHN M , BERTZ RICHARD J
IPC: C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34 , A61K31/451 , A61K45/06
Abstract: There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.
-
公开(公告)号：AT225186T
公开(公告)日：2002-10-15
申请号：AT96922604
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALE J , LEONARD JOHN M , BERTZ RICHARD J
IPC: C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34 , A61K45/06 , A61K31/451
Abstract: There is described a combination of ritonavir or a pharmaceutically acceptable salt thereof in combination with another HIV protease inhibitor, formulated as a single or separate composition, for use in the inhibition or treatment of an HIV infection or AIDS in a human host.
-
公开(公告)号：CA2224738A1
公开(公告)日：1997-01-16
申请号：CA2224738
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： LEONARD JOHN M , KEMPF DALE J , BERTZ RICHARD J , NORBECK DANIEL W
IPC: C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34 , A61K45/00
Abstract: A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
-
公开(公告)号：ES2328559T3
公开(公告)日：2009-11-16
申请号：ES02079004
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALES J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/426 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/431 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/473 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
Abstract: Uso de ritonavir o una sal farmacéuticamente aceptable del mismo para mejorar la farmacocinética de un fármaco (o una sal farmacéuticamente aceptable del mismo) que se metaboliza por citocromo P450 monooxigenasa.
-
公开(公告)号：ES2304416T3
公开(公告)日：2008-10-16
申请号：ES02079003
申请日：1996-06-28
Applicant: ABBOTT LAB
Inventor： NORBECK DANIEL W , KEMPF DALES J , LEONARD JOHN M , BERTZ RICHARD J
IPC: A61K31/426 , C07D243/04 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/34 , A61K31/341 , A61K31/395 , A61K31/425 , A61K31/44 , A61K31/4427 , A61K31/445 , A61K31/453 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/535 , A61K31/5375 , A61K31/55 , A61K31/7048 , A61K38/05 , A61K38/06 , A61K38/13 , A61K38/55 , A61P31/12 , A61P31/18 , C07D217/22 , C07D277/24 , C07D277/28 , C07D295/08 , C07D295/18 , C07D303/46 , C07D307/20 , C07D401/14 , C07D417/12 , C08F2/34
Abstract: Una combinación de ritonavir o una sal farmacéuticamente aceptable del mismo y un fármaco que es metabolizado por citocromo P450 monooxigenasa 3A4, para mejorar la farmacocinética del fármaco, siempre que el fármaco sea distinto a un inhibidor de VIH proteasa.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.023 seconds)
